Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 17, 2017

Primary Completion Date

April 25, 2023

Study Completion Date

April 25, 2023

Conditions
Asthma, Aspirin-Induced
Interventions
DRUG

Ifetroban Oral Capsule

Subjects will be treated with oral ifetroban daily for 8 weeks

DRUG

Placebo Oral Capsule

Subjects will be treated with oral placebo daily for 8 weeks

Trial Locations (16)

10461

Montefiore Medical Center, The Bronx

14607

Rochester Regional Health, Rochester

19104

University of Pennsylvania, Philadelphia

22908

University of Virginia Medical Center, Charlottesville

27104

Wake Forest Baptist Health, Winston-Salem

30308

Emory University School of Medicine, Sinus, Nasal, and Allergy Center, Atlanta

33013

The Research Center, Hialeah

37232

Vanderbilt University Medical Center, Nashville

40207

Advanced ENT & Allergy, Louisville

47713

Deaconess Clinic, Evansville

66210

Kansas City Allergy and Asthma Associates, PA, Overland Park

85724

Banner University of Arizona Medical Center, Asthma & Airway Disease Research Center, Tucson

92130

Scripps Clinic - Carmel Valley, San Diego

93534

Antelope Valley Clinical Trials, Lancaster

94305

Stanford University Medical Center, Stanford

75390-9035

UT Southwestern Medical Center, Dallas

Sponsors
All Listed Sponsors
lead

Cumberland Pharmaceuticals

INDUSTRY